

Immuno-hemolytic Anemia

Antibody-mediated red-cell destruction

Warm antibody

IgG • 37°C

Cold agglutinin

IgM • low temperature

Cold hemolysin

IgG • biphasic

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com


Learning objectives

- Explain immune mechanisms of premature erythrocyte destruction.
- Interpret direct and indirect antiglobulin tests.
- Distinguish warm, cold agglutinin, and cold hemolysin patterns.
- Link pathogenesis to morphology, symptoms, and management principles.

Defining immunohemolytic anemia

- Antibodies recognize erythrocytes and shorten their survival.
- Red-cell injury can be mediated through phagocytes or complement.
- An ingested medication may initiate the immune reaction.

Schematic



Antigen-bearing red cell

Antibody binding determines the
immune mechanism

Why the terminology matters

Immunohemolytic

Includes antibodies induced by a drug

Emphasizes immune mechanism rather than origin

Autoimmune hemolytic

Often used for the same clinical group

Strictly implies an immune response to self antigens

The hemolytic-anemia context

- Premature erythrocyte destruction shortens red-cell survival below the normal 120 days.
- Erythropoietin rises and marrow erythropoiesis compensates.
- Products of hemoglobin degradation accumulate.

Schematic

Anemia and hemolysis

Bilirubin → jaundice

Macrophage activity

Where red cells are destroyed

Extravascular

Sequestration and phagocytosis in spleen, liver, or marrow


Often accompanies reduced red-cell deformability

Intravascular

Red cells rupture within the circulation

Complement activation can be responsible


A shared response to premature hemolysis



The peripheral blood shows reticulocytosis when compensation is effective.

Extravascular hemolysis: Signature consequences

- Splenic sequestration accompanies reduced red-cell deformability.
- Persistent phagocytosis can produce splenomegaly.
- Anemia, jaundice, and splenic enlargement are major clinical features.



Intravascular hemolysis: Signature consequences

- Free plasma hemoglobin can exhaust haptoglobin binding.
- Hemoglobinemia and red-brown hemoglobinuria may follow.
- Renal hemosiderosis and iron loss can occur with persistent hemolysis.

Schematic

Intravascular RBC lysis



Free Hb → hemoglobinuria

Morphologic response to chronic hemolysis

- Increased marrow erythroid precursors reflect compensatory erythropoiesis.
- Reticulocytes increase in peripheral blood.
- Hemosiderin can accumulate in macrophage-rich organs.
- Prolonged hemolysis may cause pigment gallstones.

Schematic

Anemia and hemolysis

Bilirubin → jaundice

Macrophage activity

Three immunohemolytic patterns

Type	Dominant antibody	Characteristic setting
Warm antibody	IgG (occasionally IgA); active at 37°C	Primary, autoimmune disease, neoplasm, drug
Cold agglutinin	IgM; avid binding at 0–4°C	Infection or chronic B-cell disorder
Cold hemolysin	IgG; binds in cooler tissues	Typically postviral children

Mechanistic classification

Antibody binds the red cell



Fc receptor or complement
engagement




Extravascular removal or in-
circulation lysis

The antibody class, thermal behavior, and effector pathway explain the distinct phenotypes.

Diagnostic principle: Demonstrate immune coating

- Testing seeks immunoglobulin and/or complement on patient erythrocytes.
- The direct antiglobulin (Coombs) test identifies such surface coating.
- The indirect test examines antibody reactivity in patient serum.



Direct antiglobulin test: Analytic steps

Obtain patient erythrocytes



Add anti-human Ig /
complement reagent




Observe whether
erythrocytes agglutinate

Visible clumping supports the presence of surface-bound human Ig or complement.

What a positive direct Coombs test means

- Antiglobulin reagent bridges erythrocytes coated with human Ig or complement.
- The reaction demonstrates coating, not the degree of red-cell destruction.
- Interpret the reaction together with evidence of hemolysis.



Indirect antiglobulin test: Analytic steps

Patient serum is obtained



React serum with antigen-
defined test red cells



Observe antigen-dependent
reactivity

This method helps characterize target specificity and temperature dependence.

Direct versus indirect antiglobulin testing

Direct test

Analyte: Coating on patient red cells

Uses anti-human Ig/complement to reveal in-vivo binding

Direct evidence for immune red-cell sensitization

Indirect test


Analyte: Antibodies in patient serum

Uses test cells with defined antigens

Helps define target specificity and temperature behavior


Start with the phenotype, not the test alone

- Identify evidence of shortened red-cell survival and compensatory erythropoiesis.
- Determine whether destruction is predominantly extravascular or intravascular.
- Use immune testing to define the antibody-mediated component.




Warm antibody type: Relative frequency

- Approximately 80% of immunohemolytic anemias are warm-antibody type.
- Antibodies bind stably to erythrocytes at 37°C.
- Most are IgG; IgA accounts for less common cases.



Warm antibodies at core body temperature


- Binding remains stable at physiologic body temperature.
- Circulating coated red cells encounter Fc-receptor-bearing phagocytes.
- This favors extravascular rather than direct intravascular destruction.



Warm autoantibody antigen targets

- In primary disease, the initiating cause is not known.
- Antibodies often recognize red-cell surface proteins.
- Proteins associated with the Rh blood-group complex are frequent targets.


Schematic



Antigen-bearing red cell

Antibody binding determines the
immune mechanism


Warm hemolysis: Fc-mediated clearance




The antibody marks the cell for recognition; Membrane loss transforms its mechanics.

Partial phagocytosis is not complete lysis

- Macrophages remove portions of the erythrocyte membrane.
- Loss of surface area without equivalent volume loss produces spherocytes.
- These cells have less capacity to deform through splenic channels.




Why spherocytes are destroyed in the spleen



The same shape-to-sequestration principle appears in hereditary spherocytosis.


Spherocytes: Finding and differential

- In warm immunohemolysis, spherocytes reflect acquired membrane loss.
- An inherited membrane defect can also produce spherocytes.
- The immune mechanism is distinguished by appropriate antiglobulin evidence.



Why the spleen becomes enlarged

- Continued erythrocyte removal increases splenic phagocytic activity.
- Macrophage hyperplasia underlies the usual moderate splenomegaly.
- The organ is both a site of injury and a clinical marker of chronicity.



Warm antibody anemia: Etiologic categories

Primary

Approximately 50% of warm cases are idiopathic

Cause of loss of immune tolerance remains unknown


Secondary

Autoimmune disorders, especially systemic lupus erythematosus

Lymphoid neoplasms or drug exposure


Warm immune hemolysis and systemic autoimmunity

- Systemic lupus erythematosus is an important associated disorder.
- The hemolytic process remains antibody-mediated.
- Recognizing a systemic setting changes the etiologic classification.



Warm immune hemolysis and lymphoid neoplasms


- Lymphoid neoplasms can underlie a secondary warm-antibody process.
- The red-cell injury is immune-mediated, not necessarily direct neoplastic infiltration.
- Seek the associated condition when disease is not idiopathic.



Medication-triggered immune hemolysis

- Some drugs initiate an antibody response that injures red cells.
- Two mechanisms are emphasized: New antigenic determinants and loss of tolerance.
- Distinguishing them clarifies the antibody target.

Schematic



New antigenic determinant on red cell

Antigenic-drug mechanism

**Drug attaches to
erythrocyte
membrane**



A new antigenic
determinant forms



Antibodies recognize
drug-associated cell




Opsonization or
complement injury
follows

Penicillin and cephalosporins are examples.

Antigenic-drug timing and exposure

- Typically follows large intravenous doses of the offending drug.
- Onset around 1–2 weeks after therapy begins.
- Drug bound to the red-cell membrane is recognized by antibody.

Schematic



New antigenic determinant on red cell

Drug-associated red-cell destruction routes

Extravascular route

Antibodies function as opsonins

Phagocytes remove coated erythrocytes

More common in the described antigenic-drug mechanism

Intravascular route

Antibody may fix complement

Complement-mediated injury lyses red cells within the circulation

Reported but less common in this mechanism

Tolerance-breaking drug mechanism

**A medication disrupts
immune tolerance**



Autoantibodies
against native
erythrocyte antigens
appear



Rh-complex targets
are common



Clinical hemolysis may
develop

The exact process through which tolerance is disrupted is unknown.

α -Methyldopa: The prototype

- The classic tolerance-breaking example is α -methyldopa.
- About 10% of exposed individuals develop detectable red-cell autoantibodies.
- Roughly 1% develop clinically significant hemolysis.

Schematic

Drug exposure




Immune tolerance disrupted

Autoantibody to native RBC antigen

Antibody positivity is not equivalent to anemia

- A positive direct antiglobulin test indicates surface-bound immune material.
- The α -methyldopa example shows that immune sensitization may be clinically silent.
- Evidence of active red-cell destruction is still needed for interpretation.




Drug-related immune mechanisms compared

Feature	Antigenic-drug mechanism	Tolerance-breaking mechanism
Initial event	Drug binds RBC and creates determinant	Drug disrupts tolerance
Target of antibody	Drug-associated membrane complex	Native RBC antigens (often Rh)
Classic examples	Penicillin; cephalosporins	α -Methyldopa
Dominant injury	Opsonization; sometimes complement	Autoantibody-mediated RBC removal

Principles of warm-antibody management


- Identify and remove initiating factors such as causative drugs when possible.
- When this cannot be achieved, immunosuppressive medication is a mainstay.
- Splenectomy targets a key site of red-cell sequestration and destruction.



Cold agglutinin type: The defining antibody

- IgM antibodies bind red cells strongly at low temperatures, especially 0–4°C.
- They do not bind stably at 37°C.
- This category accounts for approximately 15–20% of immunohemolytic anemia.

Schematic



IgM-mediated red-cell
agglutination

Cold agglutinins: Acute and chronic settings

Acute / transient

May follow an infection

Most such antibodies produce little clinically significant hemolysis

Chronic


May be idiopathic

May be associated with certain B-cell neoplasms

Infectious associations of cold agglutinins

- *Mycoplasma pneumoniae* is a classic association.
- Epstein–Barr virus and cytomegalovirus are reported triggers.
- Influenza virus and HIV are additional associations.

Schematic




The site and temperature of binding
determine the outcome

Why many infection-related cases resolve

- Cold agglutinins may arise only transiently during an infection.
- The textbook characterizes these episodes as self-limited.
- Clinically important hemolysis is uncommon in such episodes.

Schematic




IgM-mediated red-cell
agglutination

Chronic cold agglutinin disease: Context

- An idiopathic form is described.
- Certain B-cell neoplasms are associated with chronic disease.
- These cases can be more difficult to treat than transient episodes.

Schematic




Antibody-coated erythrocyte
Recognition precedes premature
destruction

Cold exposure creates permissive vascular sites

- Exposed fingers, toes, and ears can cool substantially.
- IgM can bind erythrocytes where vascular temperatures fall below about 30°C.
- Peripheral cold exposure therefore creates a localized risk of red-cell agglutination.

Schematic



The site and temperature of binding
determine the outcome

Cold agglutinin mechanism: First phase

**Peripheral blood
cools**



IgM attaches to
erythrocytes



Red cells agglutinate




Complement fixation
begins

IgM binding is rapid in cool vascular beds.

Cold-dependent red-cell agglutination


- Multivalent IgM promotes visible erythrocyte clumping.
- Agglutination is a physical vascular event, not by itself the entire hemolytic process.
- The location of clumping helps explain acrocyanotic symptoms.

Schematic



IgM-mediated red-cell
agglutination


Cold agglutinin mechanism: Warming phase



Transient coating can still be sufficient for opsonization.


C3b explains delayed erythrocyte clearance

- Sublytic C3b deposits remain on the erythrocyte membrane.
- C3b is an efficient opsonin for macrophage recognition.
- Subsequent destruction occurs mainly outside blood vessels.




Sites of extravascular cold-antibody hemolysis

- C3b-opsonized red cells can be removed by phagocytes.
- The spleen, liver, and bone marrow participate.
- Hemolytic severity varies across affected patients.



Why intravascular lysis is usually absent


- IgM commonly dissociates as circulating blood warms.
- It often departs before the complement cascade causes complete lysis.
- C3b-mediated extravascular clearance is therefore typical.



Cold-related microvascular obstruction

- Agglutinated erythrocytes can impair peripheral vascular flow.
- Pallor and cyanosis may occur in cold-exposed sites.
- Raynaud phenomenon is another recognized consequence.

Schematic




IgM-mediated red-cell
agglutination

Cold symptoms are mechanistically distinct

- Vascular symptoms arise from aggregation in peripheral vessels.
- Anemia arises from accelerated clearance of sensitized erythrocytes.
- A patient may exhibit both effects of the same IgM response.

Schematic




The site and temperature of binding
determine the outcome

Principle of managing chronic cold agglutinin anemia

- Avoidance of low environmental temperatures when feasible.
- This reduces conditions favorable to peripheral IgM binding.
- Associated conditions may complicate the clinical course.

Schematic



The site and temperature of binding determine the outcome

Warm and cold agglutinin types: Mechanistic contrasts


Variable	Warm antibody type	Cold agglutinin type
Principal antibody	IgG; occasionally IgA	IgM
Thermal behavior	Stable binding at 37°C	Binding strongest in cold
Main opsonin	IgG / Fc engagement	C3b after transient IgM
Hemolytic compartment	Predominantly splenic	Spleen, liver, marrow
Clinical emphasis	Spherocytes and splenomegaly	Cold-related acrovascular symptoms

Cold hemolysin type: A separate entity

- This form causes paroxysmal cold hemoglobinuria.
- The responsible antibody is IgG, not IgM.
- It is a rare but potentially severe intravascular hemolytic disorder.

Schematic

P antigen




IgG binds on cooling; Complement lysis follows warming

Paroxysmal cold hemoglobinuria: Antigen target

- Cold hemolysin IgG recognizes the P blood-group antigen.
- Binding occurs in cooler peripheral tissue vascular beds.
- The red-cell target differs from that of typical warm antibodies.

Schematic

P antigen



IgG binds on cooling; Complement lysis follows warming

Biphasic hemolysis in paroxysmal cold hemoglobinuria

IgG binds P antigen in the cold



Antibody sensitizes erythrocytes to complement



Blood recirculates to the warm core



Complement-mediated intravascular lysis

Binding and lysis are favored at different temperatures.

Why the hemoglobinuria can be dramatic

- Complement injury causes red cells to rupture in the circulation.
- Released hemoglobin can appear in plasma and urine.
- Hemolysis can be substantial and occasionally fatal.

Schematic

Intravascular RBC lysis




Free Hb → hemoglobinuria

The characteristic pediatric context

- Most described cases occur in children following viral infections.
- The disorder is usually transient in that setting.
- Most affected children recover within about one month.

Schematic



The site and temperature of binding
determine the outcome

Cold agglutinins versus cold hemolysins

Feature	Cold agglutinin	Cold hemolysin
Antibody class	IgM	IgG
Early cold event	Cell agglutination + C3b	Binding to P antigen
On warming	IgM often dissociates	Complement-mediated lysis
Dominant outcome	Extravascular removal	Intravascular hemolysis
Typical association	Infection or B-cell neoplasm	Postviral childhood episode

Case exercise: Warm antibody pattern

Illustrative clinical scenario

An adult has anemia, splenic enlargement, spherocytes, and antibodies detected on their erythrocytes.

Interpretive question

Which immune effector explains the spherocytes?

Mechanistic interpretation

IgG-coated cells engage macrophage Fc receptors; Partial phagocytosis removes membrane, reducing deformability and favoring splenic clearance.

Case exercise: Cold agglutinin pattern

Illustrative clinical scenario

An adult develops pallor and cyanosis of exposed fingers in cold weather; Erythrocytes agglutinate in cooled blood.

Interpretive question

Why can the same process cause anemia?

Mechanistic interpretation

Cold-bound IgM fixes complement. Residual C3b promotes later macrophage clearance after IgM dissociates in warmer blood.

Case exercise: Biphasic cold hemolysis

Illustrative clinical scenario

A child develops red-brown urine after a recent viral illness; An IgG antibody binds red cells in cold peripheral blood.


Interpretive question

Which mechanism explains intravascular hemolysis?

Mechanistic interpretation

Cold-reactive IgG binds P antigen; Complement activity after rewarming can lyse the red cells within the circulation.

A mechanistic diagnostic sequence




This sequence links a laboratory finding to a pathophysiologic diagnosis.

Three patterns: One immune principle

Warm	Cold agglutinin	Cold hemolysin
Binding at 37°C	Cold IgM binding	Cold IgG binds P antigen
IgG–Fc receptor axis	C3b opsonization	Lysis on rewarming
Partial phagocytosis → spherocytes	Extravascular clearance + vascular clumping	Intravascular hemoglobin release

Integrated clinicopathologic synthesis


- Spherocytes point toward membrane removal and splenic sequestration.
- Cold-triggered acral symptoms point toward erythrocyte agglutination.
- Hemoglobinuria in postviral childhood illness raises the cold-hemolysin pattern.
- The direct antiglobulin test supplies immune evidence, not the whole diagnosis.



Key learning points

- Antibody thermal behavior determines where sensitization occurs.
- The effector mechanism—not simply the presence of antibody—determines hemolysis.
- Warm IgG favors splenic clearance; Cold IgM favors C3b opsonization.
- Biphasic cold-reactive IgG can cause major intravascular hemolysis.

Schematic



Antigen-bearing red cell

Antibody binding determines the
immune mechanism

Primary reference and source limitations

- Robbins, Cotran & Kumar: Pathologic Basis of Disease, 11th ed. (2026).
- Chapter 14: Red Blood Cell and Bleeding Disorders, pp. 579–580 and 590–591.
- Text and table facts were adapted from the supplied Robbins Markdown; original chapter PDF images were not supplied or reproduced.